R42 — 2024 Investments
3 investments dated 2024 · listed companies and verified rows first · show all
Abselion develops measurement tools and a platform combining hardware, purpose-built assay formats, and software for biological measurements such as protein quantification.
BiotechDeep TechHardwareMedical DevicesCambridge, GB
Dr Ruizhi Wang(CEO)
Co-investorsCambridge Angels groupM Ventures
Healx is an AI-powered biotech company that discovers and develops treatments for rare diseases.
AI & Machine LearningBiotechDigital HealthHealthtechCambridge, GB
Tim Guilliams(Co-founder & CEO)in
Co-investorsAmadeus Capital PartnersBalderton CapitalCambridge Angels groupIntel CapitalSCI VenturesAtomico
Healx uses artificial intelligence to redevelop, combine, and enhance known compounds to build a pipeline of therapies for rare diseases, with an expanding focus on oncology and preventing cancer recurrence.
AI & Machine LearningBiotechHealthtech
Tim Guilliams(Founder)in
Co-investorsAurum Venture PartnersVU Venture PartnersAtomico
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.